Tyrosine Kinase Inhibitors (TKI), Mitogen-activated Extracellular signal-regulated Kinase (MEK) and B- Rapidly Accelerated Fibrosarcoma (BRAF) kinase inhibitors and immunotherapy are currently used for treating thyroid cancer patients. This evidence concerns the gene BRAF and thyroid cancer.